25 Multiple Sclerosis Plr Articles – Video

Posted on by


25 Multiple Sclerosis Plr Articles
ll4.me 25 Multiple Sclerosis Plr Articles 25 Multiple Sclerosis Articles - Private Label Rights Article Topics:- Treatment For Multiple Sclerosis With No Side Effects Types Of Multiple Sclerosis What Multiple Sclerotic People Should Avoid during Christmas How To Diagnose Multiple Sclerosis How To Know If It Is A Multiple Sclerosis Relapse How To Treat Multiple Sclerosis Is Cannabis Use Beneficial For Multiple Sclerosis Lifesaving Drug For Multiple Sclerosis More Information On Multiple Sclerosis Multiple Sclerosis Association Of America All About Multiple Sclerosis Causes Of Multiple Sclerosis Childbirth May Slow Multiple Sclerosis Common Human Bacteria Triggers Multiple Sclerosis Good News On Pregnancy And Multiple Sclerosis How Is Multiple Sclerosis Classified The Clinical Part Of Multiple Sclerosis The History Of Multiple Sclerosis The Kurtzke Expanded Disability Status Scale And Multiple Sclerosis Multiple Sclerosis Differential Diagnoses Not Everyone With Multiple Sclerosis Is On Treatment Pathophysiology Of Multiple Sclerosis Stem Cell Therapy Reverses Multiple Sclerosis Symptoms Of Multiple Sclerosis Teenage Obesity and Multiple Sclerosis Use the content on : Blogs/Content Pages Report Social Sites ecourses Convert to Audios ebook Bundle and Sell as Products Personal Education, Tips Training Whatever you might imagine... RIGHTS:- [YES] Can Be Sold [YES] Can Be Packaged [YES] Can Be Offered As a Bonus [YES] Can Be Added As Web Content [YES] Can Be Used For Product ...From:rebeccahenson9854Views:0 0ratingsTime:00:14More inPeople Blogs

View original post here:

25 Multiple Sclerosis Plr Articles - Video

Charles – USA Stem Cells Testimonial – Video

Posted on by


Charles - USA Stem Cells Testimonial
If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.From:USAStemcellsViews:4 0ratingsTime:10:04More inScience Technology

Read the original post:

Charles - USA Stem Cells Testimonial - Video

Bone marrow stem cell therapy does not improve short-term recovery after heart attack

Posted on by

Washington, November 8 (ANI): Administering to patients stem cells derived from their own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial.

The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous, related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function.

Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

"This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN.

"Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. With TIME and LateTIME, we have established both safety and baseline results in two large studies that followed the same procedures for growing and then administering stem cells. This standard will inform the next steps in research on the use of stem cells to repair damaged hearts," she stated.

Fellow CCTRN member Jay Travese, M.D., of the Minneapolis Heart Institute added, "With this baseline now set, we can start to adjust some of the components of the protocol to grow and administer stem cell to find cases where the procedure may improve function."

"For example, this therapy may work better in different population groups, or we might need to use new cell types or new methods of delivery," he noted.

Skarlatos said that another advantage of the TIME study is that CCTRN is storing samples of the stem cells taken from the participants. Investigators can examine the relationship between people who showed significant improvement during the study and the characteristics of their stem cells. Such a comparison may offer insights on the cell traits that are associated with clinical improvement.

The findings will be presented at the American Heart Association (AHA) 2012 Scientific Sessions in Los Angeles and will appear concurrently in the Journal of the American Medical Association. (ANI)

Originally posted here:

Bone marrow stem cell therapy does not improve short-term recovery after heart attack

Stem cell therapy improves heart function 2 years after heart attack

Posted on by

Washington, November 7 (ANI)

Stem cell therapy improves heart function in patients who had previous heart attacks, according to researchers from the University of Louisville and Brigham and Women's Hospital.

In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks.

They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat.

No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration - new heart tissue replacing former dead tissue killed by heart attack.

"The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient," said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL.

"The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study," he stated.

The trial - called SCIPIO for Stem Cell Infusion in Patients with Ischemic CardiOmyopathy - was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower; the normal LVEF is 50 percent or higher.

The investigators harvested the CSCs, referred to as "c-kit positive" cells because they express the c-kit protein on their surface, from 33 patients during coronary artery bypass surgery. The stem cells were purified and processed in Anversa's lab in Boston so that they could multiply. Once an adequate number of stem cells was produced - about one million for each patient - Bolli's team in Louisville reintroduced them into the region of the patient's heart that had been scarred by the heart attack.

The researchers reported that in the 20 patients receiving CSCs, LVEF increased from 29 percent to 36 percent at four months following infusion. None of the 13 control patients in the trial received CSCs and this group showed, on average, no improvement.

See the rest here:

Stem cell therapy improves heart function 2 years after heart attack

Stem cell therapy to be regulated in PH

Posted on by

MANILA, Philippines -- The Department of Health (DOH) has announced its plan to regulate stem cell therapy in the country.

Stem cell treatment involves the use of adult stem cells to treat a range of diseases.

The Health Department believes that because of the complex preparation and invasive procedure involved, there needs to be a regulatory framework to protect Filipino citizens.

The regulation of laboratories and practitioners involves five key points.

First is a check on the credentials of people involved in the service, as stem cell treatment is a specialized field. The supply of raw materials will also have to be monitored, making sure especially that they do not come from aborted fetuses.

Laboratories will be scrutinized for their procedures, sanitation and safety. Therapeutic claims, on the other hand, are also up for strict assessment, to make sure that these are based on solid scientific evidence.

Finally, the DOH also wants a report on the possible failure of treatments, to find out if there are negative outcomes to stem cell therapy.

"Those who are going to other countries for stem cell treatment should also check if their destination allows stem cell tourism," clarified FDA Acting Director Dr. Kenneth Hartigan-Go.

The DOH said consultations with stakeholders are still ongoing, but it expects a set of guidelines to be released by next month.

Original post:

Stem cell therapy to be regulated in PH

Promising Stem Cell Research Driving Industry's Growth in 2012

Posted on by

NEW YORK, NY--(Marketwire - Nov 8, 2012) - Stem cell stocks have been gaining popularity among investors in 2012 as new and promising research continues to propel the industry forward. A study performed earlier this year at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on Aastrom Biosciences, Inc. ( NASDAQ : ASTM ) and Neostem Inc. ( NYSE : NBS ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/ASTM

http://www.FiveStarEquities.com/NBS

A more recent study, also conducted at Johns Hopkins University, has showed that stem cells donated by strangers were as safe and as effective as the patient's own cells in repairing heart tissue. This is a key advancement for the treatment of heart attack with stem cells, as this possibly means stem cells could be stored for use just as blood is now.

"You could have the cells ready to go in the blood bank so when the patient comes in for a therapy -- there's no delay," said Dr. Joshua Hare of the University of Miami. "It's also cheaper to make the donor cells," as marrow from a single donor could provide enough cells for the treatment of up to 10 people.

Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Aastrom Biosciences is a leader in the development of patient-specific multicellular therapies for the treatment of severe, chronic cardiovascular diseases. Stem cell therapy is the infusion, injection or transplantation of whole cells into a patient for the treatment of a disease or condition.

NeoStem is a provider of adult stem cell collection, processing and storage services in the United States, enabling healthy individuals to donate and store their stem cells for personal therapeutic use. In addition, the company collects and stores cord blood cells of newborns which help to ensure a supply of autologous stem cells for the child should they be needed for future medical treatment.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

See original here:

Promising Stem Cell Research Driving Industry's Growth in 2012

Stem cell therapy using patient's own cells after heart attack does not enhance cardiac recovery

Posted on by

Public release date: 6-Nov-2012 [ | E-mail | Share ]

Contact: Steve Goodyear sgoodyear@mhif.org 952-807-8365 Minneapolis Heart Institute Foundation

MINNEAPOLIS, MN November 6, 2012 Administering autologous stem cells obtained from bone marrow either 3 or 7 days following a heart attack did not improve heart function six months later, reports a new clinical trial supported by the National Institutes of Health. The results of this trial, called TIME (Transplantation In Myocardial Infarction Evaluation), were presented by Jay Traverse, MD of the Minneapolis Heart Institute Foundation Tuesday, Nov. 6, at the 2012 Scientific Sessions of the American Heart Association in Los Angeles.

The results of this trial mirror a previous, related study (LateTIME) which found that autologous bone marrow stem cell therapy given 2-3 weeks after a heart attack did not improve cardiac recovery. Both TIME and LateTIME were carried out by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

"The data presented by TIME do much to advance stem cell therapy research," said Jay Traverse, MD of the Minneapolis Heart Institute Foundation and Principal Investigator of this study. "While this study did not provide a demonstrated cardiac benefit after six months, we still learned a great deal. Together, TIME and Late TIME have shown that stem cell therapy is safe, and they have set a baseline in terms of quantity of stem cells, type of stem cells, and severity of heart attack."

TIME enrolled 120 volunteers (avg. age 57) between July 2008 and February 2011; the participants all had moderate to severe impairment in their left ventricle and had undergone coronary stent placement as treatment for the heart attack. The participants were randomly assigned to one of four groups: day 3 stem cell, day 3 placebo (inactive cells), day 7 stem cell, or day 7 placebo. The CCTRN researchers developed a method of processing and purifying the stem cells from the bone marrow of each volunteer to ensure everyone received a uniform dose (150 million stem cells).

Heart improvement was assessed six months after stem cell therapy by measuring the percentage of blood that gets pumped out of the left ventricle during each contraction (left-ventricular ejection fraction, or LVEF). The study found no significant differences between the change in LVEF readings at the six month follow-up in either the Day 3 or Day 7 stem cell groups compared with placebo or with each other; every group showed about a 3 percent improvement in LVEF. However, the researchers found that younger patients randomized to Day 7 had greater improvement in their LVEF compared to their placebo counterparts

"The lack of six-month improvement seen for TIME and, prior to that, LateTIME, does not mean stem cell therapy is not a viable post-heart attack strategy," said Traverse. "Because we have this data we can start to address some parameters; for example this therapy may work better in younger people, or maybe we need to use cells from healthy volunteers (allogeneic) since their cells may provide greater therapeutic benefit. There will also be upcoming studies using novel cell types which we look forward to using in future clinical trials."

###

For further information see:

See the rest here:

Stem cell therapy using patient's own cells after heart attack does not enhance cardiac recovery

Pluristem shares bounce back after Thursday plunge

Posted on by

NEW YORK (AP) Shares of biotechnology company Pluristem Therapeutics Inc. bounced back Friday after the company responded to a report that a patient treated with its PLX stem cell therapy had died.

THE SPARK: Bloomberg BusinessWeek reported Thursday that Pluristem did not disclose the death of a young patient who had been treated with its placental cell therapy before a $32 million public stock sale in September. Shares of Pluristem fell 23 percent Thursday.

The Israeli company said Thursday evening that parts of the article were inaccurate or misleading. It said the patient, a Romanian girl whose name has not been disclosed, was "in imminent danger of death" at the time she was treated with the stem cells. She was not part of an organized clinical trial and was treated on a compassionate basis because no therapy options remained.

Pluristem said the patient lived for six months after her treatment. She returned to Romania four months before she died and the company was not monitoring her health. Pluristem said it was not aware of her death at the time it sold the additional stock. Bloomberg said the patient died Sept. 12, the day the stock sale was announced. The sale closed a week later.

"The formal report relating to the death clearly stated that there was no connection between the PLX cell treatment and the death of the patient," Pluristem said in a press release.

THE BIG PICTURE: Pluristem said that three patients have been treated with PLX on a compassionate basis including the Romanian girl and two have died. The company said it believes the patients lived longer than expected following treatment, which demonstrates that PLX therapy can be effective. The company is studying the stem cells as a treatment for peripheral artery disease, nerve pain, and other conditions.

THE STOCK: Shares of Pluristem rose 39 cents, or 13.7 percent, to $3.24 on Friday. The stock reached an annual high of $5 per share in August, and including Friday's gains, the shares are down 29 percent since the company announced the stock offering.

Continue reading here:

Pluristem shares bounce back after Thursday plunge

DOH to regulate stem cell therapy in PH

Posted on by

Published on 10 November 2012 Hits: 112 Written by Jovee Marie N. Dela Cruz

The Department of Health (DOH) on Friday said that it has become necessary to issue regulations for stem cell therapy in the country. Health Secretary Enrique Ona said that guidelines for clinics offering stem cell therapy will be released immediately by the DOH and the Food and Drug Administration.

We will issue guidelines because here in the country we dont know where the stem cell offered by clinics come from, he said.

According to the DOH, stem cell therapy belongs to the category of advanced cell therapy, which includes biologics and blood. Many countries apply a risk-based approach to assess the quality, efficacy and safety of advanced cell therapy.

In many countries, stem cell is considered an investigational intervention, Ona said.

The DOH said that stem cell research employs both autologous (from same person) or allogenic (from another organism like an animal or another human cell or tissue sample) method.

Ona said that because there are many steps in the preparation of this lab and invasive procedure, there is a need to have a regulatory framework to protect Filipino citizens.

Here is the original post:

DOH to regulate stem cell therapy in PH

Studies On Stem Cell Therapy After Heart Attack Show Mixed Results

Posted on by

April Flowers for redOrbit.com Your Universe Online

Conflicting studies were highlighted at this years American Heart Association Scientific Sessions meeting concerning stem cell therapy for heart attack patients.

The first study, from the University of Louisville and Brigham and Womens Hospital, reported holy grail results for a Phase I clinical trial: marked sustained improvement in all patients with zero adverse effects.

Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Womens Hospital presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks in a Late-Breaking Clinical Trial session.

The researchers report that all patients receiving the stem cell therapy showed improved heart function after two years, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF). LVEF is a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. They saw no adverse effects from the therapy. In fact, nine patients showed evidence of myocardial regeneration new tissue replacing formerly dead tissue killed by heart attack in MRI scans.

The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient, said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL. The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study.

In all patients, cells with high regenerative reserve were obtained and employed therapeutically, said Anversa, professor of Anesthesia and Medicine at Brigham and Womens Hospital and Harvard Medical School. Our efforts to carefully characterize the phenotype and growth properties of the cardiac stem cells may have contributed to these initial positive results.

The Stem Cell Infusion in Patients with Ischemic CardiOmyopathy, or SCIPIO, trial was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower. A normal LVEF reading is 50 percent or higher.

The CSCs, referred to as c-kit positive cells because they express the c-kit protein on their surface, were harvested from 33 patients during coronary artery bypass surgery. The stem cells were then purified and processed so that they could multiply, and once an adequate number was produced about one million for each patient they were reintroduced into the region of the patients heart that suffered scarring during the heart attack.

At four months after infusion, the researchers report that LVEF increased from 29 percent to 36 percent for 200 patients. On average, the 13 control patients who did not receive a CSC infusion showed any improvement.

Original post:

Studies On Stem Cell Therapy After Heart Attack Show Mixed Results

DOH warns against use of stem cells from aborted babies

Posted on by

By Philip C. Tubeza Philippine Daily Inquirer

The Department of Health (DOH) on Saturday warned those contemplating stem cell therapy against using stem cells from aborted babies and human embryos.

The DOH issued the statement as it reviewed the legal and technical specifications of stem cell therapy to come up with a regulatory framework.

The Philippine government will not allow the use of aborted fetuses or human embryos (as sources of stem cells). There is a need to ensure that the biological raw materials are documented and validated and follow infection-free procedures, the health department said.

There is also a need to know if the materials to be injected came from animal or human tissues, it added.

The DOH said the other fundamental areas of the regulatory framework would include the monitoring of the marketing claims by medical centers that offer stem cell therapy so that the claims stick within the boundaries of science as objectively as possible.

Credentials and procedures

The credentials of the scientists involved should also match the training, education and skills required for these procedures while good laboratory procedures should be observed in the preparation of the tissue and cells, the DOH said.

The centers to be regulated or accredited will have to show both positive and negative outcomes for a better handle of the predictors of success or failure from this intervention, it said.

The health department said there was a need for a regulatory framework because there were many steps in the preparation of stem cell therapies and the government had been receiving many queries about it.

Here is the original post:

DOH warns against use of stem cells from aborted babies

Wildwood Castle – Petersburg Tn – Herbert W Armstrong’s – What Is True Spirituality? Church Of God – Video

Posted on by


Wildwood Castle - Petersburg Tn - Herbert W Armstrong #39;s - What Is True Spirituality? Church Of God
Herbert W Armstrong #39;s radio broadcast explains what the Bible really teaches concerning Spirituality. Music : Seize The Hour - Philadelphia Singers - Herbert W Armstrong College Epic Music of Sadness Information on Church Of God teaching @ Trumpet.com Tomorrows World.org COGwriter Herbert W Armstrong Searchable Library Body of Christ UniteFrom:WildwoodCastleViews:2 0ratingsTime:30:03More inEducation

See the article here:

Wildwood Castle - Petersburg Tn - Herbert W Armstrong's - What Is True Spirituality? Church Of God - Video

Ted Bundy Interview [Ted Bundy] – Video

Posted on by


Ted Bundy Interview [Ted Bundy]
Watch full movie here : free-hot-movies.com Ted Bundy Bundy Ted slashers and serial killers January 23 stephen michaud Chronic Metal Illness michael reilly burke Interview self control videos Violation of Rights Capital Punishment Abnormal Psychology Altered Perception john henry browne Documentary seattle attorney jennifer tisdale franoise gillard Charles Manson Movie Collage Serial Killer movieclipsdotcom Lack of Remorse melissa schmidt hamish mcalpine Serial #AMG:V 267699 bow tie videos laura de casto electric chair interview part michael santos matthew bright michael muscal mirror videos window videos Killer Movie xxxchurch.com on louise bundy 20th century water videos killer serialkiller conversation christianity spirituality Instrumental Manipulation Intimidation pornography Dobson (2002) lust videos risk videos movie clips deliverance documentary Psychopathy Psychopath Disorder James January 24 bra videos van videos confession washington interviews Sociopathy turnsignal Trailer 1989 2002 kill education execution interview /m/094w3q /m/0gjtg9 Education Sociopath Arrogance violence Director November religion ViolenceFrom:TrudieKlawuhnsViews:0 0ratingsTime:09:51More inFilm Animation

Continue reading here:

Ted Bundy Interview [Ted Bundy] - Video

What it Takes to Bring You the Best Tasting Organic Walnuts – Video

Posted on by


What it Takes to Bring You the Best Tasting Organic Walnuts
http://www.dancingtreepeople.com Organic Walnuts, fresh from the farm. In this video we load up Loretta #39;s Toyota Corolla and head out to the co-op drop point. Dancing TreePeople Farm is an organic orchard and garden located in Upper Lake, California. The farm embraces the ethics and principles of permaculture and organic growing. We grow organic walnuts and sell them online and at the farm, conduct tours of our orchard and garden, and promote permaculture and eco-spirituality through Growing Edge, our monthly e-zine.From:DancingTreePeopleViews:0 0ratingsTime:02:48More inFilm Animation

Originally posted here:

What it Takes to Bring You the Best Tasting Organic Walnuts - Video

Organic Walnuts: Getting Ready for the Walnut Harvest at Da – Video

Posted on by


Organic Walnuts: Getting Ready for the Walnut Harvest at Da
http://www.dancingtreepeople.com Organic Walnuts, fresh from the farm. In this video we get ready for the harvest and share why what we do results in the best tasting walnuts. Dancing TreePeople Farm is an organic orchard and garden located in Upper Lake, California. The farm embraces the ethics and principles of permaculture and organic growing. We grow organic walnuts and sell them online and at the farm, conduct tours of our orchard and garden, and promote permaculture and eco-spirituality through Growing Edge, our monthly e-zine.From:DancingTreePeopleViews:0 0ratingsTime:01:06More inFilm Animation

The rest is here:

Organic Walnuts: Getting Ready for the Walnut Harvest at Da - Video